📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer. (2020)

First Author: Kocher HM

Attributed to: MICA: Early phase clinical trial repurposing ATRA as stromal targeting agent in a novel drug combination for pancreatic cancer (STAR-PAC) funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1038/s41467-020-18636-w

PubMed Identifier: 32973176

Publication URI: http://europepmc.org/abstract/MED/32973176

Type: Journal Article/Review

Volume: 11

Parent Publication: Nature communications

Issue: 1

ISSN: 2041-1723